Sue E. Ashley
Royal Marsden NHS Foundation Trust · 141 works · 9,367 citations · h-index 56
Top works
- Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
- Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer.
- Immunohistochemical localization of c-erbB-2 in human breast carcinomas
- A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer
- A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer
- Randomized, Placebo-Controlled Trial of Clodronate in Patients With Primary Operable Breast Cancer
- Prognostic factors in small cell lung cancer: A simple prognostic index is better than conventional staging
- Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?
- Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas
- Craniopharyngioma — long-term results following limited surgery and radiotherapy
- Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer.
- Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]
- Postoperative radiotherapy in the management of spinal cord ependymoma
- Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma
- Hypofractionated radiotherapy as palliative treatment in poor prognosis patients with high grade glioma
- The Royal Marsden Hospital pilot tamoxifen chemoprevention trial
- Validation of the Royal Marsden Hospital Prognostic Index in Advanced Esophagogastric Cancer Using Individual Patient Data From the REAL 2 Study
- Platinum-based chemotherapy in triple-negative breast cancer
- Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer
- The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study